JEREMY ROLLINS: Open Payments
NPI 1659510147 · WINNSBORO, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$678 in 39 payments from 13 companies in 2025. Trend: 2023 $828 · 2024 $705 · 2025 $678
Food & beverage: $678
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 6 | $107 |
| Otsuka America Pharmaceutical, Inc. | 5 | $102 |
| Novo Nordisk Inc | 6 | $101 |
| Astellas Pharma US Inc | 5 | $84 |
| ABBVIE INC. | 4 | $78 |
| Phathom Pharmaceuticals, Inc. | 3 | $41 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $33 |
| PFIZER INC. | 2 | $30 |
| Amgen Inc. | 2 | $29 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $26 |
Products named: REXULTI, JARDIANCE, Veozah, VRAYLAR, Ozempic, MOUNJARO, VOQUEZNA, Rybelsus.
Industry payments across LA — which companies pay providers there.
